ATE437637T1 - Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren - Google Patents

Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren

Info

Publication number
ATE437637T1
ATE437637T1 AT02766876T AT02766876T ATE437637T1 AT E437637 T1 ATE437637 T1 AT E437637T1 AT 02766876 T AT02766876 T AT 02766876T AT 02766876 T AT02766876 T AT 02766876T AT E437637 T1 ATE437637 T1 AT E437637T1
Authority
AT
Austria
Prior art keywords
nitric oxide
treating
pharmaceutically acceptable
acceptable salt
compositions
Prior art date
Application number
AT02766876T
Other languages
English (en)
Inventor
David Garvey
Original Assignee
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc filed Critical Nitromed Inc
Application granted granted Critical
Publication of ATE437637T1 publication Critical patent/ATE437637T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
  • Pyrane Compounds (AREA)
AT02766876T 2001-05-02 2002-05-01 Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren ATE437637T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28772501P 2001-05-02 2001-05-02
PCT/US2002/013667 WO2002087508A2 (en) 2001-05-02 2002-05-01 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use

Publications (1)

Publication Number Publication Date
ATE437637T1 true ATE437637T1 (de) 2009-08-15

Family

ID=23104065

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02766876T ATE437637T1 (de) 2001-05-02 2002-05-01 Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren

Country Status (8)

Country Link
US (2) US7138430B2 (de)
EP (1) EP1406608B1 (de)
JP (2) JP2004528337A (de)
AT (1) ATE437637T1 (de)
AU (1) AU2002338528B2 (de)
CA (1) CA2446064A1 (de)
DE (1) DE60233140D1 (de)
WO (1) WO2002087508A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005051295A2 (en) * 2003-11-21 2005-06-09 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
EP1718286A4 (de) * 2004-01-22 2010-03-31 Nicox Sa Nitrosierte und/oder nitrosylierte verbindungen, zusammensetzungen und anwendungsverfahren
WO2005102304A1 (en) * 2004-04-23 2005-11-03 Northern Sydney And Central Coast Area Health Service Methods and compositions for the treatment of myocardial conditions
US7838552B2 (en) * 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CN101862322A (zh) 2004-07-30 2010-10-20 托伦特药物有限公司 奈必洛尔及其药学可接受盐、制备方法以及奈必洛尔的药物组合物
CA2576255A1 (en) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
WO2006083780A2 (en) * 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Glucuronidated nebivolol
US20060222592A1 (en) * 2005-04-05 2006-10-05 Clemens Burda Nanoparticles and methods of manufacturing nanoparticles for electronic and non-electronic applications
EP1877553B1 (de) 2005-05-02 2011-01-19 ANP Technologies, Inc. Polymerkonjugat-verbesserte bioassays
JP2008545742A (ja) * 2005-05-31 2008-12-18 マイラン ラボラトリーズ インク． ネビボロールを含む組成物
WO2007041676A2 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. The genetic risk assessment in heart failure: impact of genetic variation of aldosterone synthase promoter polymorphism
US20070154466A1 (en) * 2005-12-30 2007-07-05 Jan Weber Internal medical devices containing peroxide-converting catalysts
US20080193385A1 (en) * 2007-02-08 2008-08-14 Todd Maibach Compositions and methods for treating neuropathy
CA2599082A1 (en) * 2007-08-27 2009-02-27 Ping I. Lee Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds
WO2009026697A1 (en) * 2007-08-28 2009-03-05 University Of Manitoba A method of reducing a vasodilatory response using a guanylate cyclase pathway inhibitor or an h2o2 reducing agent
TW200918099A (en) 2007-09-14 2009-05-01 Nitto Denko Corp Drug carriers
WO2010014263A1 (en) 2008-08-01 2010-02-04 Arca Discovery, Inc. Methods and compositions involving (s)-bucindolol
HUP0800498A2 (en) * 2008-08-06 2010-03-29 Semmelweis Egyetem Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
US11207109B2 (en) 2010-10-20 2021-12-28 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
CN102977068A (zh) * 2012-05-03 2013-03-20 中国药科大学 一氧化氮供体型异色满酮类衍生物、其制备方法及用途
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
WO2014111443A1 (en) * 2013-01-18 2014-07-24 Synlab Services Gmbh Prediction of kidney disease progression using homoarginine as a biomarker
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
EP4183372A1 (de) 2016-01-29 2023-05-24 Neovasc Tiara Inc. Klappenprothese zur vermeidung von abflussverstopfung
US11173235B2 (en) 2016-07-15 2021-11-16 Cook Regentec Llc Nitrite eluting devices and methods of use thereof
JP2019535415A (ja) 2016-11-21 2019-12-12 ニオバスク ティアラ インコーポレイテッド 経カテーテル心臓弁送達システムの急速退却のための方法およびシステム
US10856984B2 (en) 2017-08-25 2020-12-08 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
CA3082900A1 (en) 2017-11-17 2019-05-23 Renovion, Inc. Stable ascorbic acid compositions and methods of using the same
EP3768378A4 (de) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. Neuartiges verfahren zur verlangsamung der ventrikulären rate
BR112020024083A2 (pt) 2018-05-25 2021-05-04 Arca Biopharma Inc. métodos e composições envolvendo bucindolol para o tratamento de fibrilação atrial
US11737872B2 (en) 2018-11-08 2023-08-29 Neovasc Tiara Inc. Ventricular deployment of a transcatheter mitral valve prosthesis
WO2020206012A1 (en) 2019-04-01 2020-10-08 Neovasc Tiara Inc. Controllably deployable prosthetic valve
CN113924065A (zh) 2019-04-10 2022-01-11 内奥瓦斯克迪亚拉公司 具有自然血流的假体瓣膜
CN114025813B (zh) 2019-05-20 2024-05-14 内奥瓦斯克迪亚拉公司 具有止血机构的引入器
JP2022537559A (ja) 2019-06-20 2022-08-26 ニオバスク ティアラ インコーポレイテッド 薄型人工補綴僧帽弁
WO2022198259A1 (en) * 2021-03-25 2022-09-29 The Heart Research Institute Ltd Treatment methods for pulmonary arterial hypertension

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US311175A (en) 1885-01-27 And joseph l
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
US4868179A (en) 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
US5428061A (en) 1988-09-15 1995-06-27 Schwarz Pharma Ag Organic nitrates and method for their preparation
US5284872A (en) 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
DK1023905T3 (da) 1991-11-14 2005-05-30 Brigham & Womens Hospital Farmaceutisk præparat indeholdende S-nitroso-immunoglobuliner og anvendelse deraf
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5650447A (en) 1992-08-24 1997-07-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitric oxide-releasing polymers to treat restenosis and related disorders
DE4321306A1 (de) 1993-06-26 1995-01-05 Sanol Arznei Schwarz Gmbh Disulfide
TW355683B (en) 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
US5874461A (en) 1994-12-28 1999-02-23 Janssen Pharmaceutica N.V. Use of Nebivolol as an anti-atherogenic
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5932538A (en) 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5807847A (en) 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
JP2001504457A (ja) 1996-11-01 2001-04-03 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
CA2293501A1 (en) 1997-07-03 1999-01-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Nitric oxide-releasing amidine-derived diazeniumdiolates, compositions and uses thereof
IT1301759B1 (it) 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
WO2000049993A2 (en) 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
IT1308633B1 (it) 1999-03-02 2002-01-09 Nicox Sa Nitrossiderivati.
IT1311923B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311921B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
IT1314184B1 (it) * 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
US6635273B1 (en) * 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency
IT1320176B1 (it) 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
KR20060120164A (ko) 2003-12-02 2006-11-24 니콕스 에스. 에이. 항고혈압제의 니트록시유도체들
PL380065A1 (pl) 2003-12-02 2006-12-11 Nicox S.A. Nitrooksypochodne karwedilolu i inne beta blokery jako leki przeciwko nadciśnieniu

Also Published As

Publication number Publication date
EP1406608B1 (de) 2009-07-29
AU2002338528B2 (en) 2008-01-24
US7384976B2 (en) 2008-06-10
WO2002087508A3 (en) 2003-12-11
JP2010248226A (ja) 2010-11-04
EP1406608A2 (de) 2004-04-14
DE60233140D1 (de) 2009-09-10
EP1406608A4 (de) 2004-10-20
US20060009513A1 (en) 2006-01-12
US7138430B2 (en) 2006-11-21
JP2004528337A (ja) 2004-09-16
WO2002087508A2 (en) 2002-11-07
CA2446064A1 (en) 2002-11-07
US20040132805A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
ATE437637T1 (de) Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
UA84420C2 (ru) СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
ECSP056210A (es) Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad
NO20055219L (no) Nye forbindelser
ECSP055525A (es) Inhibidores de cinasas de tirosina
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
SE9800836D0 (sv) New Compounds
GB0112348D0 (en) Compounds
DE60324544D1 (de) Muskarin antagonisten
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
EE200400031A (et) Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat
NO20041060L (no) Krystaller av hydroksynorefedrinderivat
WO2003103602A3 (en) SELECTIVE INHIBITORS OF NITROSED AND / OR NITROSYLATED CYCLOOXIGENASE-2, COMPOSITIONS AND METHODS OF USE
CY1108224T1 (el) Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
DK1532131T3 (da) Motilid-forbindelser
WO2004002420A3 (en) Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
RS20060206A (en) Aminopyridine-derivatives as inducible no-synthase inhibitors
WO2004012686A3 (en) Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
WO2004010945A3 (en) Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
IL166103A0 (en) Pyrrolidine derivatives and their use
BR0312183A (pt) Uso de compostos benzisosselenazolonas contra lesão miocárdica isquêmica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties